Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00063999 · OUTCOME

Number of Participants Alive at Time of Last Follow-up by Estrogen or Progesterone Receptor Status (Positive or Negative)

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer · Source last updated 2021-10-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Patients were assessed during treatment. Following completion of treatment, follow up was assessed every 3 months for 2 years, then every 6 months for 3 years and annually thereafter, for a maximum of 10 years.

What was measured

The time alive in months from study entry to last contact or death.

Analysis population: Eligible patients with estrogen and progesterone receptor data.

Groups in this outcome

Estrogen Receptor Positive

Patients with estrogen receptor positive tumors

Estrogen Receptor Negative

Patients with estrogen receptor negative tumors

Progesterone Receptor Positive

Patients with progesterone receptor positive tumors

Progesterone Receptor Negative

Patients with progesterone receptor negative tumors

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Estrogen Receptor Positive919
Estrogen Receptor Negative355
Progesterone Receptor Positive832
Progesterone Receptor Negative440

Reported measurements

Source class 1

Alive

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Estrogen Receptor Positive408Not reportedNot reportedNot reportedNot reported
Estrogen Receptor Negative90Not reportedNot reportedNot reportedNot reported
Progesterone Receptor Positive380Not reportedNot reportedNot reportedNot reported
Progesterone Receptor Negative117Not reportedNot reportedNot reportedNot reported

Dead

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Estrogen Receptor Positive511Not reportedNot reportedNot reportedNot reported
Estrogen Receptor Negative265Not reportedNot reportedNot reportedNot reported
Progesterone Receptor Positive452Not reportedNot reportedNot reportedNot reported
Progesterone Receptor Negative323Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        408
      2. group Id
        OG001
        value
        90
      3. group Id
        OG002
        value
        380
      4. group Id
        OG003
        value
        117
      title
      Alive
    2. measurements
      1. group Id
        OG000
        value
        511
      2. group Id
        OG001
        value
        265
      3. group Id
        OG002
        value
        452
      4. group Id
        OG003
        value
        323
      title
      Dead
denoms
  1. counts
    1. group Id
      OG000
      value
      919
    2. group Id
      OG001
      value
      355
    3. group Id
      OG002
      value
      832
    4. group Id
      OG003
      value
      440
    units
    Participants
description
The time alive in months from study entry to last contact or death.
groups
  1. description
    Patients with estrogen receptor positive tumors
    id
    OG000
    title
    Estrogen Receptor Positive
  2. description
    Patients with estrogen receptor negative tumors
    id
    OG001
    title
    Estrogen Receptor Negative
  3. description
    Patients with progesterone receptor positive tumors
    id
    OG002
    title
    Progesterone Receptor Positive
  4. description
    Patients with progesterone receptor negative tumors
    id
    OG003
    title
    Progesterone Receptor Negative
param Type
COUNT_OF_PARTICIPANTS
population Description
Eligible patients with estrogen and progesterone receptor data.
reporting Status
POSTED
time Frame
Patients were assessed during treatment. Following completion of treatment, follow up was assessed every 3 months for 2 years, then every 6 months for 3 years and annually thereafter, for a maximum of 10 years.
title
Number of Participants Alive at Time of Last Follow-up by Estrogen or Progesterone Receptor Status (Positive or Negative)
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice